LivingGLP1
Study S002104

A Multi-centre, Prospective, Non-interventional Single-arm Study Investigating Clinical Parameters Associated With the Use of Once-daily Oral Semaglutide in a Real-world Adult Population With Type 2 Diabetes in Mexico

Registration

Registration
NCT05316662
Study type
OBSERVATIONAL
Status
COMPLETED
Enrollment
187
Start
2022-04-06
Primary completion
2024-04-06
Lead sponsor
Novo Nordisk A/S
Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG:Semaglutide
Results posted
FALSE
Individual participant data sharing
YES
Secondary identifiers
OTHER:U1111-1240-4396

Registered primary outcomes

  • Change in HbA1c [From baseline (week 0) to End of Study visit (V3) (week 34-44)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.